ZOLL Wins Patent Infringement Case Against ELan Med GmbH

  ZOLL Wins Patent Infringement Case Against ELan Med GmbH

German Company Ordered to Halt Manufacture and Sale of Infringing Products for
                           Therapeutic Hypothermia

Business Wire

CHELMSFORD, Mass. -- March 11, 2013

ZOLL Medical Corporation, a manufacturer of medical devices and related
software solutions, announced today that the District Court of Munich,
Germany, ruled in favor of ZOLL in granting an injunction against ELan Med
GmbH of Cologne, Germany, for infringing on a ZOLL patent through the
distribution and sale of certain ELan products for use with ZOLL’s
Intravascular Temperature Management (IVTM™) systems.

Under the terms of the judgment, ELan has been ordered to stop the manufacture
and sale of infringing products for use with ZOLL’s patented temperature
management systems (the Thermogard XP^® and CoolGard 300^® intravascular
temperature management systems). The court also ruled that ZOLL is entitled to
recover damages resulting from sales of the infringing products that were
incurred since January 18, 2012, and ordered ELan to pay 90% of the cost of
the court proceedings.

“We place a high value on our intellectual property and will pursue all
available legal remedies against companies or individuals who attempt to
capitalize on our innovative technologies by patent infringement,” said James
Palazzolo, President of ZOLL. “We are gratified that the court has
acknowledged ZOLL’s temperature management system patent.”

ZOLL’s IVTM system provides cooling and warming through a balloon catheter
inserted into the patient’s venous system. A startup kit is used to connect
the Thermogard XP or CoolGard 300 temperature management console with a
catheter to either warm or cool the saline as it flows through the catheter.
This approach provides more accurate control of core body temperature than
surface methods can, since it directly cools or warms the patient’s blood as
it flows through the body.

Since the saline flows only within the catheter, no fluid is infused into the
patient. ZOLL offers a variety of triple-lumen catheters with placement
options to handle specific patient challenges. The ZOLL IVTM system is
efficient, precise, and easy to use, and frees up clinical staff to attend to
other patient needs.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets
medical devices and software solutions that help advance emergency care and
save lives, while increasing clinical and operational efficiencies. With
products for defibrillation and monitoring, circulation and CPR feedback, data
management, fluid resuscitation, and therapeutic temperature management, ZOLL
provides a comprehensive set of technologies that help clinicians, EMS and
fire professionals, and lay rescuers treat victims needing resuscitation and
critical care. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding
company Asahi Kasei Corp., with operations in the chemicals and fibers, homes
and construction materials, electronics, and health care business sectors. Its
health care operations include devices and systems for critical care,
dialysis, therapeutic apheresis, transfusion, and manufacture of
biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and
nutritional products. With more than 25,000 employees around the world, the
Asahi Kasei Group serves customers in more than 100 countries. For more
information, visit www.asahi-kasei.co.jp/asahi/en/.

Copyright © 2013 ZOLL Medical Corporation. All rights reserved. CoolGard,
IVTM, Thermogard, and ZOLL are trademarks or registered trademarks of ZOLL
Medical Corporation in the United States and/or other countries. Asahi Kasei
is a registered trademark of Asahi Kasei Corporation. All trademarks are the
property of their respective owners.

Contact:

ZOLL Medical Corporation
Diane Egan, +1-978-421-9637
degan@zoll.com
 
Press spacebar to pause and continue. Press esc to stop.